Positive Two-Year Data Boost Prospects For Vivus' Qnexa
This article was originally published in The Pink Sheet Daily
Executive Summary
Firm reports continued weight loss advantage as well as improvement in weight-related co-morbidities, which has been a request from FDA's advisory committee.